ES2964286T3 - Método de tratamiento de la Esteatohepatitis no alcohólica avanzada - Google Patents

Método de tratamiento de la Esteatohepatitis no alcohólica avanzada Download PDF

Info

Publication number
ES2964286T3
ES2964286T3 ES15788807T ES15788807T ES2964286T3 ES 2964286 T3 ES2964286 T3 ES 2964286T3 ES 15788807 T ES15788807 T ES 15788807T ES 15788807 T ES15788807 T ES 15788807T ES 2964286 T3 ES2964286 T3 ES 2964286T3
Authority
ES
Spain
Prior art keywords
compound
formula
liver
group
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15788807T
Other languages
English (en)
Spanish (es)
Inventor
Kazuko Matsuda
Yuichi Iwaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Application granted granted Critical
Publication of ES2964286T3 publication Critical patent/ES2964286T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Alcoholic Beverages (AREA)
  • Steroid Compounds (AREA)
ES15788807T 2014-05-08 2015-05-06 Método de tratamiento de la Esteatohepatitis no alcohólica avanzada Active ES2964286T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461990606P 2014-05-08 2014-05-08
US201462042072P 2014-08-26 2014-08-26
US14/490,618 US9346754B2 (en) 2014-05-08 2014-09-18 Method of treating advanced non-alcoholic steatohepatitis
PCT/US2015/029457 WO2015171755A2 (en) 2014-05-08 2015-05-06 Method of treating advanced non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
ES2964286T3 true ES2964286T3 (es) 2024-04-05

Family

ID=54367221

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15788807T Active ES2964286T3 (es) 2014-05-08 2015-05-06 Método de tratamiento de la Esteatohepatitis no alcohólica avanzada

Country Status (10)

Country Link
US (1) US9346754B2 (OSRAM)
EP (1) EP3139911B1 (OSRAM)
JP (1) JP6672173B2 (OSRAM)
KR (1) KR102386018B1 (OSRAM)
CN (1) CN106456576A (OSRAM)
BR (1) BR112016025369A2 (OSRAM)
CA (2) CA2946597C (OSRAM)
ES (1) ES2964286T3 (OSRAM)
TW (1) TW201622716A (OSRAM)
WO (1) WO2015171755A2 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457306B2 (en) * 2014-10-07 2016-10-04 Life Technologies Corporation Regulated vacuum off-gassing of gas filter for fluid processing system and related methods
EP4346783A1 (en) * 2021-05-28 2024-04-10 MediciNova, Inc. Phenoxyalkylcarboxylic acid derivatives and their use in lowering triglyceride levels

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2585246A1 (fr) 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4788055A (en) 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4816264A (en) 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
US4985585A (en) 1988-03-07 1991-01-15 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process for their preparations
US4996047A (en) 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5290812A (en) 1991-01-18 1994-03-01 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process of preparing the same
US7060854B2 (en) 2003-06-24 2006-06-13 Medicinova, Inc. Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid
US7064146B2 (en) 2003-06-24 2006-06-20 Medicinova, Inc. Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use
MXPA06012564A (es) * 2004-04-27 2007-01-31 Medicinova Inc Derivados de acido fenoxialquilcarboxilico en el tratamiento de enfermedades inflamatorias.
WO2009109525A1 (en) * 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
JP2013056834A (ja) * 2011-09-07 2013-03-28 Okayama Univ 線維化疾患治療剤
US8835499B2 (en) * 2011-12-08 2014-09-16 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis

Also Published As

Publication number Publication date
BR112016025369A2 (pt) 2017-08-15
KR102386018B1 (ko) 2022-04-14
CA3205812A1 (en) 2015-11-12
KR20170003581A (ko) 2017-01-09
CA2946597C (en) 2023-09-12
WO2015171755A2 (en) 2015-11-12
JP2017518967A (ja) 2017-07-13
EP3139911A4 (en) 2017-12-20
EP3139911A2 (en) 2017-03-15
CN106456576A (zh) 2017-02-22
EP3139911B1 (en) 2023-10-25
US9346754B2 (en) 2016-05-24
CA2946597A1 (en) 2015-11-12
US20150322004A1 (en) 2015-11-12
JP6672173B2 (ja) 2020-03-25
TW201622716A (zh) 2016-07-01

Similar Documents

Publication Publication Date Title
JP6250588B2 (ja) Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
ES2755183T3 (es) Compuestos ppar para uso en el tratamiento de enfermedades fibróticas
JP2019218379A (ja) 肝障害の治療方法
ES2727686T3 (es) Tratamiento de enfermedades que implican mucina
JP2014169321A (ja) 嚢胞性疾患の治療のためのプリン誘導体
US20240382512A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
ES2964286T3 (es) Método de tratamiento de la Esteatohepatitis no alcohólica avanzada
WO2017155053A1 (ja) 非アルコール性脂肪性肝疾患／非アルコール性脂肪性肝炎の治療剤
ES2941628T3 (es) Método de tratamiento de la fibrosis pulmonar idiopática
ES2957213T3 (es) Método para inhibir o tratar la fibrosis
CN106474126B (zh) 抗癌小分子化合物索拉非尼在治疗肝包虫病中的应用
BR122025009675A2 (pt) Usos de ácido 15-hidroxi-eicosapentaenoico (15-hepe) para o tratamento ou prevenção de distúrbios hematológicos e/ou doenças relacionadas
WO2010110268A1 (ja) 細胞死を予防するための医薬剤